| High-dose-rate Rotte "Y" applicator brachytherapy for definitive treatment of medically inoperable endometrial cancer: 10-year results. | |
| | |
MedLine Citation:
|
PMID: 18258388 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
PURPOSE: To assess the intermediate clinical outcomes of medically inoperable patients with endometrial cancer treated with definitive Rotte "Y" applicator high-dose-rate brachytherapy (HDRB) over a 10-year period. METHODS AND MATERIALS: Forty-nine inoperable patients were treated with HDRB from 1997 to 2007. Forty three (84%) were markedly obese (body mass index >35 kg/m(2)). Thirty-one patients (63.3%) underwent two-dimensional treatment planning, whereas 18 patients (36.7%) underwent three-dimensional treatment planning. Thirty five of the patients (71.4%) were first treated with external beam radiotherapy (EBRT). For patients receiving EBRT in addition to HDRB, the median Y-applicator dose was 20 Gy in 5 fractions; for patients receiving HDRB alone it was 35 Gy in 5 fractions. All patients received two Y-applicator treatments per day. RESULTS: Median follow-up time for all patients was 33 months. Acute HDRB toxicities were limited to Grade 1 and 2 occurring in 5 patients. One patient had a myocardial infarction. Four patients had late Grade 2 or 3 toxicity. Three patients had local recurrence (median time to recurrence, 16 months). The 3- and 5-year actuarial cause-specific survival rates were 93% and 87%, respectively; the overall survival rate was 83% and 42%, respectively, at 3 and 5 years. CONCLUSIONS: Twice-daily HDRB using a Y-applicator is a well-tolerated and efficacious regimen for the definitive treatment of medically inoperable patients with early-stage endometrial cancer. The recent incorporation of three-dimensional treatment planning has the potential to further decrease treatment morbidities. |
| | |
Authors:
|
Devin Coon; Sushil Beriwal; Dwight E Heron; Joseph L Kelley; Robert P Edwards; Paniti Sukumvanich; Kristin K Zorn; Thomas C Krivak |
Related Documents
:
|
6478428 - Radiation treatment of recurrent carcinoma of the vulva. 23013138 - Markers of circulating tumour cells in the peripheral blood of melanoma patients correl... 21030318 - Urethral toxicity vs. cancer control-lessons to be learned from high-dose rate brachyth... 16344258 - Intraoperative (125)i vicryl mesh brachytherapy after sublobar resection for high-risk ... 2070208 - Prognostic value of raised prostatic acid phosphatase and negative skeletal scintigraph... 8704238 - Effectiveness of intensified rotational combination chemotherapy for late hematologic r... |
Publication Detail:
|
Type: Clinical Trial; Journal Article Date: 2008-02-06 |
Journal Detail:
|
Title: International journal of radiation oncology, biology, physics Volume: 71 ISSN: 0360-3016 ISO Abbreviation: Int. J. Radiat. Oncol. Biol. Phys. Publication Date: 2008 Jul |
Date Detail:
|
Created Date: 2008-06-02 Completed Date: 2008-07-25 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7603616 Medline TA: Int J Radiat Oncol Biol Phys Country: United States |
Other Details:
|
Languages: eng Pagination: 779-83 Citation Subset: IM |
Affiliation:
|
Department of Radiation Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Aged, 80 and over Brachytherapy / adverse effects*, instrumentation*, methods Dose Fractionation Endometrial Neoplasms / radiotherapy*, surgery Female Humans Longitudinal Studies Middle Aged Radiation Injuries / diagnosis, etiology*, prevention & control Radiotherapy Dosage Treatment Outcome |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Effect of smoking during radiotherapy, respiratory insufficiency, and hemoglobin levels on outcome i...
Next Document: Identification of the minimal promoter region of the mouse NKX5-3, a transcription factor implicated...